Acepodia Announces First Patient Dosed in Phase 1 Trial of ACE723, a Novel Dual-Payload Antibody-Drug Conjugate

The Quick Take
ACE723 is the first candidate from Acepodia's AD2C platform to enter human testing ALAMEDA, Calif., and TAIPEI, Nov. 5, 2026 /PRNewswire/ -- Acepodia (6976: TT), a clinical-stage biotechnology company developing next-generation cell therapies and antibody-drug conjugates, today announced...
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire M&A.
Related
Business
Nuvoton's Gerda (TM) IC and Qt for MCUs Bring Premium User Interfaces to Cost-efficient Products without External Memory
KYOTO, Japan and ESPOO, Finland, Nov. 5, 2026 /PRNewswire/ -- Nuvoton Technology Corporation Japan (NTCJ) and Qt Group (Nasdaq Helsinki: QTCOM) jointly…
Business
ATRenew to Report Third Quarter 2026 Financial Results on November 19, 2026
SHANGHAI, Nov. 5, 2026 /PRNewswire/ -- ATRenew Inc. ("ATRenew" or the "Company") (NYSE: RERE), a pioneer in technology-driven recycling and trade-in solutions…
Business
SINBON vincula la remuneración de sus directivos a criterios ESG
-SINBON vincula la remuneración de sus directivos a criterios ESG y reduce las emisiones de alcance 1 y 2 en un 27,68 %, según su informe de sostenibilidad de…
Business
SINBON Links Executive Pay to ESG, Cuts Scope 1 and 2 Emissions 27.68% in 2025 Sustainability Report
TAIPEI, Nov. 5, 2026 /PRNewswire/ -- As sustainability thinking deepens from environmental stewardship and just transition to operational resilience, it has…
